RESUMO
Purpose - To compare the effects of lovastatin and gemfibrozil in patients with primary hyperlipidemias. Patients and Methods - Forty patients with cholesterolemia over 200 mgldl and triglyceridemia not higher than 350 mp/dl, excluded secondary causes, were selected. Twenty patients received lovastatin and 20 gemfibrozil. In order to establish the lipid profile, blood samples were taken after 2 months without medication, after 4 weeks of diet and placebo and after 6 and 12 weeks active treatment. Biochemic profile was determined before and after the treatment with active drug. Results - Thirty nine patients completed the study. Total and LDL-cholesterol were significantly reduced (p < 0.05) by both drugs but lovastatin had greater effect. Only gemfibrozil reduced triglycerides significantly. Neither drug had significant effects on HDL-cholesterol. The tolerance was satisfactory; only one patient (using gemfibrozil) needed to stop the treatment due to gastrointestinal side effects. The biochemic profïle did not present any significant alteration. Conclusion - Both drugs produced useful effects on the lipid profile. Lovastatin produced greater reductions of total and LDL-cholesterol, while gemfibrozil was more active reducing triglycerides. Neither drug changed significantly the HDL-cholesterol
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Lovastatina/uso terapêutico , Genfibrozila/uso terapêutico , Hiperlipidemias/tratamento farmacológico , Lovastatina/metabolismo , Genfibrozila/metabolismo , Hipertrigliceridemia/metabolismo , Hipertrigliceridemia/tratamento farmacológico , Colesterol/sangue , Hipercolesterolemia/metabolismo , Hipercolesterolemia/tratamento farmacológico , Hiperlipidemias/metabolismo , HDL-Colesterol/sangue , LDL-Colesterol/sangue , Análise de Variância , Triglicerídeos/sangueRESUMO
Num estudo aberto, näo comparativo, foram avaliados 20 pacientes portadores de hiperproteinemia primária, com níveis de colesterol plasmático acima de 200mg/dl e/ou triglicérides acima de 250 mg/dl, após, pelo menos, 30 dias de orientaçäo dietética. Os pacientes foram tratados com bezafibrato retard, na posologia de um comprimido de 400 mg ao dia, durante três meses. Ao término do tratamento, houve uma reduçäo significativa dos níveis séricos de colesterol total (-14,6%), triglicérides (-39,7%), bem como aumento significativo dos níveis de HDL-colesterol (+ 19,6%). As provas de funçäo hepática e renal e o hemograma dos 20 pacientes avaliados permaneceram inalterados durante o transcorrer do estudo